Progressive Pulmonary Fibrosis (PPF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Progressive pulmonary fibrosis (PPF) is a lung disease that gets worse over time. It is caused by scarring of the lungs, which makes it harder to breathe. PPF can occur in people with any interstitial lung disease (ILD). However, it is more common in people with certain types of ILD, such as idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease-related ILD (CTD-ILD), and fibrotic hypersensitivity pneumonitis. PPF is more likely to occur in older people who have smoked cigarettes, have bronchiectasis (widening of the airways), have a certain pattern of scarring on their lungs on a high-resolution computed tomography (HRCT) scan, have not had their disease improve, or stabilize, have short telomere syndrome, are Black American, or have gastroesophageal reflux disease (GERD). Certain biomarkers can be measured in the blood to help identify people who are at risk of developing PPF. These biomarkers include the MUCB promoter gene, KL-6, CCL-16, matrix metalloproteinases (MMP1, MMP7, MMP12), periostin, and tissue inhibitors of metalloproteinases (TIMP).
• PPF is more common in Europe and the United States than in other parts of the world. In Europe, the prevalence of PPF is 2.2-20.0 people per 100,000 people. In the United States, the prevalence of PPF is 28.0 people per 100,000 people.

Thelansis’s “Progressive Pulmonary Fibrosis (PPF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive Pulmonary Fibrosis (PPF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Progressive Pulmonary Fibrosis (PPF) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Progressive Pulmonary Fibrosis (PPF) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Progressive Pulmonary Fibrosis (PPF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033